BAX · Baxter International Inc
Market Cap
$13.35B
Shares
517.00M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$11.24B
+5.7%
FY2025
Net Income
-$957M
-47.5%
FY2025
Gross Margin
30.05%
-7.4pp
FY2025
Operating Margin
-2.74%
-2.9pp
FY2025
Diluted EPS
-$1.87
-47.2%
FY2025
Operating Cash Flow
$845M
-17.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $11.47B | $11.24B | $10.64B | $10.36B | $10.06B | $12.15B | $11.67B | $11.36B | $11.1B | $10.58B | $10.16B | $9.97B | $10.72B | $9.41B | $13.94B | $13.89B | $12.84B | $12.56B | $12.35B | $11.26B | |
| — | -$364M | — | — | -$442M | -$395M | -$193M | -$134M | -$71M | -$45M | -$55M | -$66M | -$126M | -$145M | -$128M | — | — | — | — | — | — | |
| — | $377M | $385M | $418M | $425M | $426M | $241M | $202M | $181M | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $8.02B | $7.87B | $6.65B | $6.21B | $6.51B | $7.43B | $7.09B | $6.6B | $6.34B | $6.11B | $6.05B | $5.82B | $6.14B | $5.25B | $6.8B | $6.85B | $6.89B | $6.04B | $6.22B | $5.74B | |
| — | $3.45B | $3.38B | $3.98B | $4.15B | $3.55B | $4.72B | $4.59B | $4.76B | $4.76B | $4.47B | $4.12B | $4.15B | $4.58B | $4.16B | $7.13B | $7.05B | $5.96B | $6.53B | $6.13B | $5.52B | |
| — | — | 30.05% | 37.46% | 40.06% | 35.29% | 38.86% | 39.3% | 41.9% | 42.88% | 42.27% | 40.5% | 41.59% | 42.74% | 44.22% | 51.19% | 50.72% | 46.39% | 51.94% | 49.64% | 49% | |
| — | $512M | $518M | $590M | $518M | $450M | $531M | $521M | $595M | $654M | $615M | $646M | $603M | $610M | $582M | $1.08B | $946M | $915M | $917M | $868M | $760M | |
| — | $2.93B | $2.89B | $2.97B | $2.95B | $3.1B | $2.85B | $2.47B | $2.54B | $2.62B | $2.63B | $2.73B | $3.09B | $3.32B | $3.08B | $3.28B | $3.15B | $2.91B | $2.73B | $2.7B | $2.52B | |
| — | $583M | $598M | $625M | $590M | $679M | $298M | $222M | $183M | $169M | $154M | $163M | $158M | $169M | $113M | $101M | $81M | $79M | — | — | — | |
| — | $953M | $981M | $997M | $984M | $1.07B | $867M | $823M | $789M | $771M | $750M | $800M | $759M | $792M | $635M | $712M | $670M | $685M | $638M | $631M | $581M | |
| — | $167M | $162M | $146M | $141M | $144M | $91M | $111M | $134M | $117M | $70M | $285M | $130M | -$6M | $161M | $150M | $192M | $257M | — | — | $70M | |
| — | -$274M | -$308M | $14M | $707M | -$2.85B | $1.35B | $1.62B | $1.77B | $1.58B | $1.29B | $745M | $449M | $656M | $496M | — | — | — | — | — | — | |
| — | — | -2.74% | 0.13% | 6.82% | -28.29% | 11.11% | 13.84% | 15.6% | 14.27% | 12.17% | 7.33% | 4.5% | 6.12% | 5.27% | — | — | — | — | — | — | |
| — | $679M | $673M | $1.01B | $1.69B | -$1.77B | $2.22B | $2.44B | $2.56B | $2.36B | $2.04B | $1.55B | $1.21B | $1.45B | $1.13B | — | — | — | — | — | — | |
| — | $296M | $290M | $408M | $508M | $413M | $207M | $153M | $111M | $93M | $85M | $89M | $146M | $167M | $155M | $113M | $92M | $115M | $117M | $148M | — | |
| — | — | $52M | $67M | $69M | $19M | $14M | $19M | $40M | $48M | $30M | $23M | $20M | $22M | $27M | $26M | $38M | $28M | $19M | $72M | — | |
| — | $37M | $41M | $38M | -$26M | -$9M | -$41M | -$190M | -$731M | $78M | -$133M | $4.28B | $105M | -$21M | $7M | $155M | -$83M | -$159M | -$45M | -$26M | -$18M | |
| — | — | — | — | — | — | — | $17M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $24M | -$1M | -$4M | $1M | -$12M | -$14M | — | |
| — | -$483M | -$505M | -$289M | $242M | -$3.25B | $1.12B | $1.29B | $970M | $1.62B | $1.1B | $4.95B | $428M | $490M | $375M | $2.89B | $2.81B | $1.89B | $2.73B | $2.46B | $2.13B | |
| — | $485M | $395M | $37M | $61M | -$135M | $83M | $182M | -$41M | $65M | $491M | -$12M | $35M | $33M | $60M | $555M | $553M | $463M | $519M | $437M | $407M | |
| — | -$1.06B | -$957M | -$649M | $2.66B | -$2.43B | $1.28B | $1.1B | $1B | $1.55B | $602M | $4.97B | $968M | $2.5B | $2.01B | $2.33B | $2.22B | $1.42B | $2.21B | $2.01B | $1.71B | |
| — | — | -8.51% | -6.1% | 25.64% | -24.19% | 10.57% | 9.44% | 8.81% | 13.93% | 5.69% | 48.85% | 9.71% | 23.3% | 21.37% | 16.69% | 16.01% | 11.06% | 17.55% | 16.31% | 15.16% | |
| — | $0 | $0 | $11M | $7M | $12M | $11M | $8M | $10M | $0 | $0 | — | — | — | — | — | $32M | $7M | $10M | $11M | $14M | |
| — | -$1.14B | -$701M | -$1.11B | $2.94B | -$2.88B | $1.22B | $1.5B | $1.28B | $1.27B | $1.32B | — | — | — | $2.85B | $2.11B | $1.77B | $1.02B | — | — | — | |
| USD/shares | — | -$2.09 | -$1.87 | -$1.27 | $5.25 | -$4.83 | $2.56 | $2.17 | $1.97 | $2.90 | $1.11 | $9.09 | $1.78 | $4.61 | $3.70 | $4.22 | $3.91 | $2.41 | $3.63 | $3.22 | $2.65 |
| USD/shares | $1.95 – $2.15* | -$2.09 | -$1.87 | -$1.27G | $5.23 | -$4.83 | $2.53G | $2.13 | $1.93 | $2.83 | $1.08 | $9.01 | $1.76 | $4.56 | $3.66 | $4.18 | $3.88 | $2.39 | $3.59 | $3.16 | $2.61 |
| shares | — | — | 513M | 510M | 506M | 504M | 502M | 509M | 509M | 534M | 543M | 546M | 545M | 542M | 543M | 551M | 569M | 590M | 607M | 625M | 644M |
| shares | — | — | 513M | 510M | 508M | 504M | 508M | 517M | 519M | 546M | 555M | 551M | 549M | 547M | 549M | 556M | 573M | 594M | 614M | 637M | 654M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $16.75B in buybacks, $11.59B in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.82×
Peer median 2.96×
EV/EBIT
—
Peer median 31.94×
P/E (TTM)
—
Peer median 39.48×
Peer medians compare against the 25 similar-size Medical Instruments & Supplies companies (of 46 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Medical Products and Therapies | $5,299,000,000 | $5,207,000,000 | $5,011,000,000 | $4,815,000,000 | $4,821,000,000 | — | — | — |
| Healthcare Systems and Technologies | $3,071,000,000 | $2,951,000,000 | $3,013,000,000 | $2,939,000,000 | $212,000,000 | — | — | — |
| Pharmaceuticals | $2,493,000,000 | $2,411,000,000 | $2,249,000,000 | $2,126,000,000 | $2,291,000,000 | — | — | — |
| Americas Segment | — | — | — | $6,710,000,000 | $6,666,000,000 | $6,321,000,000 | $6,306,000,000 | $5,951,000,000 |
| Asia Pacific Segment | — | — | — | $2,585,000,000 | $2,791,000,000 | $2,475,000,000 | $2,300,000,000 | $2,202,000,000 |
| EMEA Segment | — | — | — | $2,879,000,000 | $3,115,000,000 | $2,877,000,000 | $2,756,000,000 | $2,946,000,000 |
| Hillrom | — | — | — | $2,939,000,000 | $212,000,000 | $0 | $0 | — |
| Kidney Care | — | — | $4,453,000,000 | $4,449,000,000 | $4,682,000,000 | — | — | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $6,122,000,000 | $5,850,000,000 | $5,802,000,000 | $5,769,000,000 | $4,938,000,000 | $4,878,000,000 | $4,826,000,000 | $4,723,000,000 |
| Western Europe Canada Japan Australia and New Zealand | $3,728,000,000 | $3,436,000,000 | $3,215,000,000 | $3,035,000,000 | $4,196,000,000 | — | — | — |
| Eastern Europe Middle East Africa Latin America Asia | $1,394,000,000 | $1,350,000,000 | $1,343,000,000 | $1,253,000,000 | $3,012,000,000 | — | — | — |
| Latin America and Canada | — | — | — | $1,429,000,000 | $1,249,000,000 | $1,191,000,000 | $1,268,000,000 | $1,228,000,000 |
| Asia Pacific | — | — | — | $2,752,000,000 | $2,803,000,000 | $2,475,000,000 | $2,300,000,000 | $2,202,000,000 |
| EMEA | — | — | — | $3,709,000,000 | $3,552,000,000 | $3,129,000,000 | $2,968,000,000 | $2,946,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Infusion Therapies and Technologies | $4,101,000,000 | $4,103,000,000 | $3,960,000,000 | — | — | — | — | — |
| Care and Connectivity Solutions | $1,911,000,000 | $1,814,000,000 | $1,800,000,000 | — | — | — | — | — |
| Injectables and Anesthesia | $1,352,000,000 | $1,373,000,000 | $1,347,000,000 | — | — | — | — | — |
| Advanced Surgery | $1,198,000,000 | $1,104,000,000 | $1,051,000,000 | $998,000,000 | $977,000,000 | $886,000,000 | $875,000,000 | $798,000,000 |
| Front Line Care | $1,160,000,000 | $1,137,000,000 | $1,213,000,000 | $1,148,000,000 | $70,000,000 | $0 | $0 | — |
| Pharmaceutical Compounding | $1,141,000,000 | $1,038,000,000 | $902,000,000 | — | — | — | — | — |
| Acute Therapies | — | — | $770,000,000 | $701,000,000 | $782,000,000 | $740,000,000 | $535,000,000 | $515,000,000 |
| BioPharma Solutions | — | — | — | $644,000,000 | $669,000,000 | $486,000,000 | $469,000,000 | — |
| Chronic Renal | — | — | $3,683,000,000 | — | — | — | — | — |
| Clinical Nutrition | — | — | — | $931,000,000 | $964,000,000 | $910,000,000 | $860,000,000 | $875,000,000 |
| Medication Delivery | — | — | — | $2,886,000,000 | $2,880,000,000 | $2,691,000,000 | $2,739,000,000 | $2,664,000,000 |
| Other Product or Services | — | — | — | $140,000,000 | $109,000,000 | $105,000,000 | $126,000,000 | $509,000,000 |
| Patient Support Systems | — | — | — | $1,487,000,000 | $115,000,000 | $0 | $0 | — |
| Pharmaceuticals | — | — | — | $2,126,000,000 | $2,291,000,000 | $2,098,000,000 | $2,119,000,000 | $2,087,000,000 |
| Renal Care | — | — | — | $3,748,000,000 | $3,900,000,000 | $3,757,000,000 | $3,639,000,000 | $3,651,000,000 |
| Surgical Solutions | — | — | — | $304,000,000 | $27,000,000 | $0 | $0 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $1,633,000,000 | $1,731,000,000 | $1,856,000,000 | $1,847,000,000 | — | — | — | — |
| Medical Products and Therapies | $970,000,000 | $950,000,000 | $972,000,000 | $962,000,000 | $955,000,000 | — | — | — |
| Healthcare Systems and Technologies | $441,000,000 | $468,000,000 | $483,000,000 | $494,000,000 | $60,000,000 | — | — | — |
| Pharmaceuticals | $222,000,000 | $313,000,000 | $401,000,000 | $391,000,000 | $523,000,000 | — | — | — |
| Americas Segment | — | — | — | $2,384,000,000 | $2,612,000,000 | $2,389,000,000 | $2,499,000,000 | $2,411,000,000 |
| Asia Pacific Segment | — | — | — | $623,000,000 | $623,000,000 | $591,000,000 | $549,000,000 | $532,000,000 |
| EMEA Segment | — | — | — | $607,000,000 | $632,000,000 | $523,000,000 | $527,000,000 | $666,000,000 |
| Hillrom | — | — | — | $730,000,000 | -$80,000,000 | $0 | $0 | — |
| Kidney Care | — | — | $300,000,000 | $408,000,000 | $488,000,000 | — | — | — |
| Americas | — | — | — | — | — | — | $2,374,000,000 | $2,411,000,000 |
| Asia Pacific | — | — | — | — | — | — | $549,000,000 | $532,000,000 |
| All Other Segments | — | — | $18,000,000 | $77,000,000 | $59,000,000 | — | — | — |
| EMEA | — | — | — | — | — | — | $652,000,000 | $666,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Medical Products and Therapies | 18.3% | 18.2% | 19.4% | 20% | 19.8% | — | — | — |
| Healthcare Systems and Technologies | 14.4% | 15.9% | 16% | 16.8% | 28.3% | — | — | — |
| Pharmaceuticals | 8.9% | 13% | 17.8% | 18.4% | 22.8% | — | — | — |
| Americas Segment | — | — | — | 35.5% | 39.2% | 37.8% | 39.6% | 40.5% |
| Asia Pacific Segment | — | — | — | 24.1% | 22.3% | 23.9% | 23.9% | 24.2% |
| EMEA Segment | — | — | — | 21.1% | 20.3% | 18.2% | 19.1% | 22.6% |
| Hillrom | — | — | — | 24.8% | -37.7% | — | — | — |
| Kidney Care | — | — | 6.7% | 9.2% | 10.4% | — | — | — |
Key facts
CIK
10456
CUSIP
071813109
13F (30d)
330 filings
327 filers
Visit website
Investor relations